Starton Therapeutics has developed a proprietary transdermal technology to increase efficacy of approved drugs, to make them more tolerable, and expand their potential use.

Our lead program, STAR-LLD addresses treatment for chronic lymphocytic leukemia (CLL) and multiple myeloma (MM), two of the most common blood cancers in the US with 21,250 and 34,920 new diagnoses expected in 2021, respectively. Both CLL and MM are rarely curable. Although, current treatments extend survival for an average of three to 10 years, deteriorating quality of life remains a challenge due to drug-related side effects.

STAR-LLD, uses our proprietary continuous delivery technology to avoid the cycle of high and low drug levels caused by oral administration. This is expected to increase efficacy with fewer side effects. By rejuvenating how current treatment is dosed, Starton will be able to help even more people to benefit from a globally successful treatment.

Our mission is to transform standard of care therapies with proprietary transdermal technology, so people with cancer can receive continuous treatment to live better, longer.

Our company is led by a world-class team comprised of experienced industry professionals and clinical opinion leaders. We strengthen our capabilities through collaborations with industry-leading firms. We are committed to developing bold solutions to address unmet medical needs, moving together with quality and speed to deliver on our commitment to patients.